ALNYLAM PHARMACEUTICALS INC (DUL.DE) Stock Income Statement
Europe - Frankfurt Stock Exchange - FRA:DUL - US02043Q1076 - Common Stock
333.5 EUR
-29.6 (-8.15%)
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.21B | 2.25B | 1.83B | 1.04B | 844.30M | |||
| Cost Of Goods | 516.97M | 323.37M | 310.41M | 168.80M | 140.10M | |||
| Gross Profit | 2.69B | 1.92B | 1.52B | 868.60M | 704.10M | |||
| Operating Expenses | 2.43B | 2.10B | 1.80B | 1.65B | 1.41B | |||
| Research and Development | 1.25B | 1.13B | 1.00B | 883.00M | 792.20M | |||
| Selling, General, and Administrative Expenses | 1.18B | 975.53M | 795.65M | 770.70M | 620.60M | |||
| Operating Income | 264.70M | -176.88M | -282.18M | -785.10M | -708.70M | |||
| Interest Income/Expense | -257.96M | -193.66M | -133.60M | -259.10M | -124.20M | |||
| Other Income/Expense | 459.00K | -6.83M | -17.74M | -6.20M | -19.30M | |||
| Non Recurring Items | N/A | 0.00 | 0.00 | -76.60M | N/A | |||
| Income Before Taxes | -31.94M | -377.38M | -433.52M | -1.13B | -852.10M | |||
| Income Tax | -75.51M | -99.22M | 6.72M | 4.20M | 700.00K | |||
| Net Income | 43.56M | -278.16M | -440.24M | -1.13B | -852.80M | |||
| EBITDA | 321.02M | -120.22M | -228.12M | -740.60M | -661.10M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.23 | -2.18 | -3.52 | -9.30 | -7.20 | |||
| Non GAAP EPS | 0.51 | -2.17 | -3.56 | -8.66 | -7.12 | |||
| Statistics | ||||||||
| Gross Profit Margin | 83.90% | 85.62% | 83.02% | 83.73% | 83.39% | |||
| Profit Margin | 1.36% | -12.37% | -24.08% | -109.04% | -101.01% | |||
| Operating Profit Margin | 8.25% | -7.87% | -15.43% | -75.68% | -83.94% | |||
All data in USD